Gastrointestinal Cancer, Immune Checkpoint Inhibitors, Melanoma, Metastatic Solid Tumor, Nonsmall Cell Lung Cancer, Renal Cell Carcinoma, Squamous Cell Carcinoma
Conditions
Brief summary
The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Detailed description
Immune checkpoint inhibitors have been shown to increase survival in metastatic solid tumor patients when compared to the previously standard of care chemotherapy. Epidemiologic studies of American Indian cancer patients demonstrated having significantly worse survival when compared with Caucasians when controlled for age, sex, alcohol abuse, smoking, insurance, and disease stage. There are no current studies specifically examining the American Indian population receiving treatment with immune checkpoint inhibitors. The aim is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.
Interventions
BIOLOGICALImmunotherapy
immunotherapy
Sponsors
University of Oklahoma
Study design
Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No
Inclusion criteria
* above age 18, * histologically and cytologically confirmed NSCLC, melanoma, head and neck squamous cell carcinoma, gastrointestinal cancers,, renal cell carcinoma, or any other solid tumors where immune checkpoint therapy has been used * received immunotherapy as part of their treatment * Self-identified American Indian in ethnicity * Patients at the Stephenson Cancer Center between 2015 to 2021
Exclusion criteria
* patients who did not receive immune checkpoint inhibitor therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 1 year | Evaluating progression free survival of American Indian population vs. White population who were treated with immunotherapy |
| Overall Survival Benefit | 1 year | Evaluating the overall survival benefit of American Indian population vs. white population who were treated with immunotherapy |
| Treatment related Adverse Events | 1 year | Evaluating treatment related adverse events of American Indian population vs. white population who were treated with immunotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Difference in cancer related mortality | 1 year | Evaluate the difference in cancer related mortality in American Indian populations vs white |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORAbdul Naqash, MD
University of Oklahoma
Outcome results
None listed